Terms: = Prostate cancer AND CARS, P49589, 833, ENSG00000110619 AND Diagnosis
21 results:
1. Metabolic profiling in tissues and urine of patients with prostatic lesions and the diagnostic value of urine extracellular vesicles metabolites in prostate cancer.
Ding T; He W; Yan H; Wei Z; Zeng X; Hao X
Clin Chim Acta; 2024 Mar; 556():117845. PubMed ID: 38403146
[TBL] [Abstract] [Full Text] [Related]
2. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract] [Full Text] [Related]
3. Patient-related characteristics predict prostate cancers in men with PI-RADS 4-5 to further optimize the diagnostic performance of MRI.
Xiang L; Ma S; Xu Y; Jiang L; Guo H; Liu H; Liu Y
Abdom Radiol (NY); 2023 Dec; 48(12):3766-3773. PubMed ID: 37776336
[TBL] [Abstract] [Full Text] [Related]
4. PI-RADS
Yu R; Jiang KW; Bao J; Hou Y; Yi Y; Wu D; Song Y; Hu CH; Yang G; Zhang YD
Br J Cancer; 2023 Apr; 128(6):1019-1029. PubMed ID: 36599915
[TBL] [Abstract] [Full Text] [Related]
5. Diagnostic evaluation and incorporation of PSA density and the prostate imaging and data reporting system (PIRADS) version 2 classification in risk-nomograms for prostate cancer.
Rodríguez Cabello MA; Méndez Rubio S; Platas Sancho A; Carballido Rodríguez J
World J Urol; 2022 Oct; 40(10):2439-2450. PubMed ID: 35941245
[TBL] [Abstract] [Full Text] [Related]
6. Fast cross-staining alignment of gigapixel whole slide images with application to prostate cancer and breast cancer analysis.
Wang CW; Lee YC; Khalil MA; Lin KY; Yu CP; Lien HC
Sci Rep; 2022 Jul; 12(1):11623. PubMed ID: 35803996
[TBL] [Abstract] [Full Text] [Related]
7. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
8. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml
Gao XD; Miao Q; Zhang JL; Zhai JZ; Gui XM; Cai YH; Niu Q; Cai B
Asian J Androl; 2022; 24(2):195-200. PubMed ID: 34916475
[TBL] [Abstract] [Full Text] [Related]
9. Identification of Novel diagnosis Biomarkers for Therapy-Related Neuroendocrine prostate cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
10. Integration of quantitative diffusion kurtosis imaging and prostate specific antigen in differential diagnostic of prostate cancer.
Yao W; Zheng J; Han C; Lu P; Mao L; Liu J; Wang G; Zou S; Li L; Xu Y
Medicine (Baltimore); 2021 Sep; 100(35):e27144. PubMed ID: 34477170
[TBL] [Abstract] [Full Text] [Related]
11. Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation.
Ji X; Zhang J; Shi W; He D; Bao J; Wei X; Huang Y; Liu Y; Chen JC; Gao X; Tang Y; Xia W
Phys Eng Sci Med; 2021 Sep; 44(3):745-754. PubMed ID: 34075559
[TBL] [Abstract] [Full Text] [Related]
12. Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways.
Barrett T; Slough R; Sushentsev N; Shaida N; Koo BC; Caglic I; Kozlov V; Warren AY; Thankappannair V; Pinnock C; Shah N; Saeb-Parsy K; Gnanapragasam VJ; Sala E; Kastner C
Clin Radiol; 2019 Nov; 74(11):894.e1-894.e9. PubMed ID: 31288924
[TBL] [Abstract] [Full Text] [Related]
13. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract] [Full Text] [Related]
14. "Mix-to-Go" Silver Colloidal Strategy for prostate cancer Molecular Profiling and Risk Prediction.
Wang J; Koo KM; Wang Y; Trau M
Anal Chem; 2018 Nov; 90(21):12698-12705. PubMed ID: 30260630
[TBL] [Abstract] [Full Text] [Related]
15. Diagnostic value of medical thoracoscopy in malignant pleural effusion.
Wu YB; Xu LL; Wang XJ; Wang Z; Zhang J; Tong ZH; Shi HZ
BMC Pulm Med; 2017 Aug; 17(1):109. PubMed ID: 28778184
[TBL] [Abstract] [Full Text] [Related]
16. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
Pan X; Zhang X; Gong J; Tan J; Yin X; Tang Q; Shu K; Shen P; Zeng H; Chen N
Prostate; 2016 Jun; 76(9):823-33. PubMed ID: 27159572
[TBL] [Abstract] [Full Text] [Related]
17. Intrusive thoughts and quality of life among men with prostate cancer before and three months after surgery.
Thorsteinsdottir T; Hedelin M; Stranne J; Valdimarsdóttir H; Wilderäng U; Haglind E; Steineck G;
Health Qual Life Outcomes; 2013 Sep; 11():154. PubMed ID: 24025241
[TBL] [Abstract] [Full Text] [Related]
18. Association of census tract-level socioeconomic status with disparities in prostate cancer-specific survival.
Freeman VL; Ricardo AC; Campbell RT; Barrett RE; Warnecke RB
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2150-9. PubMed ID: 21784953
[TBL] [Abstract] [Full Text] [Related]
19. cancer prevalence in the Canadian population.
Ellison LF; Wilkins K
Health Rep; 2009 Mar; 20(1):7-19. PubMed ID: 19388364
[TBL] [Abstract] [Full Text] [Related]
20. Glycemic status and risk of prostate cancer.
Darbinian JA; Ferrara AM; Van Den Eeden SK; Quesenberry CP; Fireman B; Habel LA
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):628-35. PubMed ID: 18349280
[TBL] [Abstract] [Full Text] [Related]
[Next]
